Scale-up and deliver allogeneic cell therapies to large patient populations
On demand

Scale-up and deliver allogeneic cell therapies to large patient populations

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Scale-up and deliver allogeneic cell therapies to large patient populations

Cell therapy has become a therapeutic reality for many patients, with several successful autologous drug approvals over the last few years.

Beyond the known off-the-shelf benefits provided, allogeneic cell therapy cost structure makes this technology substantially more economical, increasing the ability of cell therapy to treat large patient populations, with many developers currently heavily investing in this field.

As allogeneic cell therapy continues its exponential growth, a scale-appropriate model to start clinical trials early, while aiding a smooth transition into large scale when the need comes, will be required for companies to successfully deliver from first-in-human to commercialization.

In this webinar, we will cover how the use of outstanding technology, alongside a tried-and-tested standardized systematic approach and reliable analytics, can enable you to deliver a robust and commercially viable process; ensuring an adequate supply to achieve your therapeutic and commercial goals.

  • The challenges associated with allogeneic cell therapy manufacturing
  • How the latest technology linked with a tried-and-tested standardized approach can successfully move you through the product lifecycle
  • How to transition from a scale-appropriate model into a commercially viable large-scale process, designed to cure the masses
  • How a stirred tank bioreactor platform can support large-scale cell manufacturing
Marcos Langtry
Marcos Langtry
Director, Commercial Development, Allogeneic Cell and Gene Therapy, Lonza

Marcos Langtry is Head of Allogeneic Cell Therapy Commercial Development at Lonza Pharma & Biotech. He is responsible for the allogeneic commercial strategy, current and future offerings, and portfolio optimization. Before joining Lonza, Marcos held several senior level positions at TiGenix, Astra Zeneca and Sanofi in the areas of external manufacturing, process development, technical operations and industrial strategy; where he acquired extensive experience with aseptically filled, biologic and cell therapy products.

Marcos Langtry holds a Master´s degree in Biochemical Engineering from University College London (UK) and an MBA from Imperial College London (UK). He is also qualified as Chartered Engineer (CEng) and Chartered Scientist (CSci).

Krishna Panchalingam
Krishna Panchalingam
Associate Director, Development Services, Cell and Gene Therapy, Lonza

Dr. Panchalingam is a Senior Scientist in the Cell and Gene Therapy Process Development group, Emerging Technologies at Lonza. He has over 14 years of experience in stem cell bioengineering, bioprocessing and in the cell and gene therapy field. Dr. Panchalingam holds a PhD degree in Chemical Engineering from the University of Calgary (Calgary, Canada) where he focused on the development of viable, scalable, and defined bioprocesses in the field of regenerative medicine.

After completing his PhD, Dr. Panchalingam started as a Bioprocess Scientist/Engineer at CCRM (Toronto, Canada), leading the development and optimization of large-scale immune cell and iPSC-based manufacturing processes and the controlled differentiation of iPSCs to cardiomyocytes.

Since joining Lonza in 2016, Dr. Panchalingam has been leading the development of new technologies and robust manufacturing processes for the clinical manufacturing of next generation cell and gene therapies.

Inbar Friedrich Ben-Nun
Inbar Friedrich Ben-Nun
Director, R&D, Cell and Gene Therapy, Lonza

Dr. Inbar Friedrich Ben-Nun is a Sr. Manager in the Cell and Gene Therapy R&D at Lonza. Inbar obtained her PhD in Molecular and Structural Biochemistry at the Hebrew University of Jerusalem. As a postdoctoral fellow at the Scripps Research Institute, CA, she acquired extensive experience with pluripotent stem cells. Her work published in “Nature Methods” showed for the first time that stem cell research could be apply to save species from extinction.

Inbar has joined Lonza in 2011, and in her current role she leads a team that focuses on developing innovative solutions to enable stem cell-based therapies.